Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | GLI1 | P08151 | 2/20 | 0.34 |
| ▸ | GLI2 | P10070 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468537 | 1.00 | ADRB3 (0.44) | ADRB3LPAR1LPAR5GLI1GLI2 | |
| SCHEMBL4474573 | 0.88 | ADRB3 (0.39) | ADRB3LPAR1LPAR5ADRB1AOC3 | |
| SCHEMBL4474577 | 0.88 | ADRB3 (0.39) | ADRB3LPAR1LPAR5ADRB1AOC3 | |
| SCHEMBL5950226 | 0.80 | AOC3 (0.35) | ADRB3AOC3 | |
| SCHEMBL6244465 | 0.79 | LPAR1 (0.36) | ADRB3LPAR1LPAR5GLI1GLI2 | |
| SCHEMBL7716904 | 0.79 | AOC3 (0.36) | ADRB3ADRB1AOC3 | |
| SCHEMBL6238984 | 0.78 | ADRB3 (0.46) | ADRB3LPAR1LPAR5GLI1GLI2 | |
| SCHEMBL6437304 | 0.78 | AOC3 (0.36) | AOC3 | |
| SCHEMBL5949849 | 0.78 | AOC3 (0.36) | AOC3 | |
| SCHEMBL5949847 | 0.78 | AOC3 (0.36) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | ADRB3 568/4885LPAR1 1377/4885LPAR5 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.